AI-generated analysis. Always verify with the original filing.
Turn Therapeutics Inc. (Nasdaq: TTRX) announced the appointment of Dr. Robert Redfield, M.D., former CDC Director, as Senior Advisor of Health Policy and Regulatory Affairs to provide strategic guidance on GX-03, its lead investigational therapy in Phase 2 clinical trials for moderate-to-severe atopic dermatitis.
Event Type
Disclosure
Voluntary
Variant
8-K
, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated February 17, 2026 104 Cover Page Interactive Data File (embedde